

**Biological  
Markers of  
Neoplasia:**  
*Basic and  
Applied  
Aspects*

**Edited by**

**RAYMOND W. RUDDON**

# **Biological Markers of Neoplasia: Basic and Applied Aspects**

Edited by  
**RAYMOND W. RUDDON, MD, PhD**

Chief, Biological Markers Laboratory, Frederick Cancer Research Center,  
Frederick, Maryland, USA



**ELSEVIER • NEW YORK**  
NEW YORK • OXFORD

© 1978 by Elsevier North Holland, Inc.

with the exception of the contributions authored by Lloyd W. Law et al. (pp. 35–46), Michael J. Rogers et al. (pp. 53–65), Stephenson et al. (pp. 95–113), Appella et al. (pp. 213–226), Rosen and Weintraub, (pp. 311–316), and Weintraub and Rosen (pp. 327–334), which are works of the United States Government.

Published by:

Elsevier North Holland, Inc.  
52 Vanderbilt Avenue, New York, New York 10017

Sole distributors outside the USA and Canada:

Thomond Books  
(A Division of Elsevier/North-Holland Scientific Publishers, Ltd.)  
P.O. Box 85  
Limerick, Ireland

Library of Congress Cataloging in Publication Data

International Conference on Biological Markers of  
Neoplasia: Basic & Applied Aspects, Leesburg, Va., 1978.  
Biological markers of neoplasia

Bibliography: p.

Includes index.

1. Cancer—Diagnosis—Congresses. 2. Tumor proteins—Congresses. 3. Tumor antigens—Congresses. 4. Viral carcinogenesis—Congresses. I. Ruddon, Raymond W. II. Title. [DNLM: 1. Antigens, Neoplasm—Congresses. 2. Antigens, Viral—Congresses. 3. Glycoproteins—Congresses. 4. Hormones, Ectopic—Congresses. 5. Neoplasms—Diagnosis—Congresses. 6. Neoplasms—Immunology—Congresses. QZ241 157b 1978]

RC270.149 1978 616.9'94'079 78-9943

ISBN 0-444-00292-8

Manufactured in the United States of America

## Preface

It is likely that improvement in cancer treatment, at least for the immediate future, will depend upon earlier diagnosis and better use of currently available treatment modalities. This realization has intensified the search for "biological markers" of cancer. A variety of tumor associated antigens, enzymes, ectopic hormones, and products of cellular metabolism have been utilized as markers for cancer in man. With few exceptions, none of these has provided the sensitivity and specificity needed for a definitive diagnostic tool in the screening for early cancer; however, a number of them have proven to be useful in evaluating a patient's response (or lack of response) to therapy and in determining disease recurrence.

The basic research currently going on in a number of related disciplines is providing new insights into the nature of gene products produced and secreted by malignant cells, and it was thought that it would be timely to bring together scientists who are experts in these fields to focus on the products of malignant cells which could be utilized in the diagnosis and treatment of cancer in man. Accordingly, the first International Conference on Biological Markers of Neoplasia: Basic & Applied Aspects was organized and held in Leesburg, Virginia on May 22-26, 1978. This volume contains the proceedings of that conference.

The goals of the conference were: (1) to provide a state of the art review of the basic research underlying the development of new cancer markers and (2) to indicate how this research can be applied to solving clinical problems in the diagnosis and therapeutic management of malignant disease. The participants represented a variety of disciplines, including biochemistry, cell biology, immunology, virology, endocrinology, and clinical oncology, and are internationally recognized as experts in their fields of research. We encouraged the participants to include an overview of their area of research as well as their most pertinent experimental data in the manuscripts. In the great majority of cases this has been done, rendering this volume an accurate and valuable representation of what was accomplished at the conference. In addition, we have included the discussions which followed each paper, and these discussions contain a number of "pearls" which add to the value of the presentations.

The conference was sponsored by Litton Bionetics, Inc. in cooperation with the National Cancer Institute - Frederick Cancer Research Center. I wish to thank the chairmen who conducted the individual

sessions: Lloyd Law (National Cancer Institute), Raymond Gilden (Frederick Cancer Research Center), Michael Crumpton (National Institute for Medical Research, Mill Hill, England), John Marchalonis (Frederick Cancer Research Center), Saul Rosen (National Institute of Arthritis, Metabolism, and Digestive Diseases), Harris Busch (Baylor College of Medicine), Edward Reich (Rockefeller University), Richard Roblin (Frederick Cancer Research Center), and Morton Schwartz (Memorial Sloan-Kettering Cancer Center). A special note of thanks goes to Dottie Green (Biological Markers Laboratory, Frederick Cancer Research Center) whose attention to detail and perseverance contributed in large measure to making the conference a success. I am also very grateful to JoAnn Tichnell (Biological Markers Laboratory), who organized and supervised the preparation of the manuscripts for this publication and to Sally Miller (Biological Markers Laboratory), who made a significant contribution to the planning of the conference and the preparation of the proceedings.

Raymond W. Ruddon, M.D., Ph.D.  
Chief, Biological Markers Laboratory  
Frederick Cancer Research Center

## Contents

Preface	xi
INTRODUCTION	
Role of Biological Markers in Cancer Diagnosis and Treatment Raymond W. Ruddon	1
SECTION I - TUMOR ASSOCIATED ANTIGENS	
Biochemical and Immunological Characteristics of Tumor Specific Antigens on Chemically Induced Rat Tumors Robert W. Baldwin, Michael R. Price and Valerie E. Moore	11
Serological Definition of Cell Surface Antigens of Chemically Induced Sarcomas of Inbred Mice Albert B. DeLeo, Hiroshi Shiku, Toshitada Takahashi and Lloyd J. Old	25
Immunogenic Properties of a Solubilized, Partially Purified Tumor Rejection Antigen (TSTA) from a Chemically Induced Sarcoma Lloyd W. Law, Ettore Appella and Garrett C. Dubois	35
The Moloney Leukemia Virus-Determined Cell Surface Antigen: Separation from Cell Membrane-Associated Virion Proteins Eva Maria Fenyo	47
Separation of the Tumor Rejection Antigen (TSTA) from the Major Viral Structural Proteins Associated with the Membrane of an R-MuLV-Induced Leukemia Michael J. Rogers, Lloyd W. Law and Ettore Appella	53
Viral Origin of Antigenic Markers in Simian Papovavirus SV40 Transformed Cells Satvir S. Tevethia, Robert Greenfield, Judith Pretell, and Mary J. Tevethia	67
Cell Surface Antigens of Human Cancer Hiroshi Shiku, Toshitada Takahashi, Thomas E. Carey, Lois A. Resnick, Herbert F. Oettgen, and Lloyd J. Old	73
SECTION II - VIRUS-ASSOCIATED CELL SURFACE ANTIGENS	
Virus-Associated Cell Surface Antigens: Introduction Raymond V. Gilden	93

Genetic Relatedness of Mammalian Type C Helper and Replication-Defective Transforming Viruses John R. Stephenson, Arifa S. Khan, Dileep N. Deobagkar, Fred H. Reynolds, Jr., Roberta K. Reynolds and Thomas L. Sacks	95
Mouse Mammary Tumor Cell Surface Antigens (CSA). I. Mouse Mammary Tumor Virus (MMTV) and Murine Leukemia Virus (MuLV) Surface-Associated Antigens Gerald Schochetman, Larry O. Arthur, Donald L. Fine and Richard Massey	115
Mouse Mammary Tumor Cell Surface Antigens. II. Immunogenicity and Expression of MMTV Proteins in the Mouse Donald Fine, Larry Arthur, Richard Massey and Gerald Schochetman	143
Membrane Glycoprotein Markers of Primate Lymphoid Cells Bruce C. Strnad, Russell H. Neubauer, and Harvey Rabin	169
SECTION III - SURFACE GLYCOPROTEINS OF NEOPLASTIC CELLS	185
Glycoproteins as Biologically Important Molecules of the Lymphocyte Membrane J.J. Marchalonis, G.W. Warr, J.M. Decker and M.J. Waxdal	187
Some Special Properties of Integral Membrane Glycoproteins of Human Red Blood Cells Vincent T. Marchesi	195
Structure of HLA Antigens Hidde L. Ploegh, Harry T. Orr, Rich Robb and Jack L. Strominger	201
Histocompatibility Antigens and Tumor-Specific Transplantation Antigens of a Methylcholanthrene-Induced Sarcoma Ettore Appella, Garret C. Dubois, T. Natori, M.J. Rogers and Lloyd W. Law	213
Cell Surface Proteins and Glycoproteins of Metastatic Murine Melanomas and Sarcomas Garth L. Nicolson	227
Orientation of Glycoproteins in Lymphocyte Plasma Membrane Michael J. Crumpton and Frank S. Walsh	241

SECTION IV - ECTOPIC HORMONES	255
Ectopic Hormones as Tumor Markers: An Overview	
Grant W. Liddle	257
The Ectopic Secretion of ACTH, MSH, Lipotrophins and Related Peptides	
Lesley H. Rees	265
Ectopic Hyperparathyroidism	
Claude D. Arnaud	275
Cancer and Inappropriate Antidiuresis	
Gary L. Robertson	277
Calcitonin as a Marker for Cancer	
Omega L. Silva and Kenneth L. Becker,	295
Ectopic Placental Lactogen	
Saul W. Rosen and Bruce D. Weintraub	311
Tumors and Human Chorionic Gonadotropin	
Judith L. Vaitukaitis	317
Ectopic Subunits of Glycoprotein Hormones	
Bruce D. Weintraub and Saul W. Rosen	327
SECTION V - DNA-BINDING PROTEINS	335
Purification of Nucleolar Antigens in Cancer Cells and Evaluation of Their Roles in Gene Function	
Harris Busch, Rose K. Busch, Frances M. Davis, Farhad Marashi, John J. Reiners and Lynn C. Yeoman	337
A DNA-Binding Protein Class Appearing in DMH-Induced Carcinogenesis	
Vincent G. Allfrey, Lidia C. Boffa and Giorgio Vidali	351
Antigenic Complexes of Chromosomal Nonhistone Proteins with DNA	
Ailsa M. Campbell, Robert C. Briggs, Marta S. Zimmer, Wanda M. Krajewska, Jen-Fu Chiu and Lubomir S. Hnilica	369
Serum DNA-Binding Proteins	
Robert G. Parsons, James A. Hoch, Robert L. Longmire, and Robert Kowal	385
Autoantibodies as Biological Markers	
Eng M. Tan, Pedro Reyes and Marvin J. Fritzler	399



Nuclear Antigens of Tumor Cell Chromatin Lynn C. Yeoman, Louis M. Woolf, Charles W. Taylor and Harris Busch	409
SECTION VI - PLASMINOGEN ACTIVATORS	419
Plasminogen Activator Production as a Possible Biological Marker for Human Neoplasia: Some Fundamental Questions Richard Roblin	421
Multiple Forms of Plasminogen Activator Judith K. Christman	433
Regulation of the Expression of Certain Biologic Markers of Neoplasia I. Bernard Weinstein, Michael Wigler, Hiroshi Yamasaki, Lih-Syng Lee, Paul B. Fisher and Allan Mufson	451
Plasminogen Activator in Normal and Malignant Cells: A Comparison of Enzyme Levels and of Hormonal Responses L. Ossowski and J. -D. Vassalli	473
Immunological Detection of Tumour Plasminogen Activator <i>In Vitro</i> and <i>In Vivo</i> Birger Åstedt	481
Activation of Plasminogen: A Widespread Mechanism for Generating Localized Extracellular Proteolysis Edward Reich	491
SECTION VII - ENZYME BIOMARKERS	501
Enzymes in Cancer - An Overview Morton K. Schwartz	503
Enzymes of Purine and Pyrimidine Metabolism as Tumor Markers M.E. Balis, J.S. Salser, P.P. Trotta, and E. Wainfan	517
Enzyme Activity Profiles and Response to Chemotherapy - A Model Applied to Breast Cancer Patients Russell Hilf, Michael L. Feldstein, Scott L. Gibson, and Edwin D. Savlov	535
Convergent Chemical Grades of Neoplasticity in Two Types of Neoplasms W. Eugene Knox	547

Urinary Nucleosides as Markers for Diagnosis and the Monitoring of Therapy	
Charles W. Gehrke, Kenneth C. Kuo, T. Phillip Waalkes, and Ernest Borek	559
Terminal Transferase and DNA Polymerases in Leukemia	
J.J. Hutton and F.J. Bollum	569
Flow Cytoenzymology: A Tool in the Search for Neoplastic Markers	
Frank Dolbeare	581
Index	587

## ROLE OF BIOLOGICAL MARKERS IN CANCER DIAGNOSIS AND TREATMENT

RAYMOND W. RUDDON

Biological Markers Laboratory, National Cancer Institute,  
Frederick Cancer Research Center, Frederick, Maryland 21701

Three of the most important questions facing clinicians involved in cancer diagnosis and treatment are: (1) How can cancer be diagnosed earlier in order to maximize the patient's chance for survival? (2) How can it be determined whether the patient's disease is responding to treatment? (3) How long should the patient be treated in the face of an apparent clinical remission? These questions are central to any good program in cancer management, but they are very difficult to answer. Definite advances have been made in the earlier diagnosis of malignant disease, exemplified by advances in exfoliative cytology (e.g., Papanicolaou test for cervical cancer), radiographic detection techniques, and endoscopic examination. The limits of the sensitivity of these methods at their best, however, usually still precludes the detection of cancers smaller than  $10^9$  cells. Thus, more sensitive tests are still needed. A number of biochemical and immunological tests for cancer have been developed in recent years. For lack of a better term, these have collectively become known as "biological markers" of cancer. Biological markers can be used in three general ways: (1) to screen the general population or specific populations at high risk for cancer development, (2) to aid in the differential diagnosis of cancer in patients who have come to the physician with signs or symptoms potentially relating to cancer, and (3) to follow the clinical course of patients with cancer. The first of these goals is by far the most difficult to accomplish because, in order for a test to be useful for screening, it must be extremely sensitive, specific for malignant disease, and cost-effective.

The need for biological markers of malignant neoplastic disease remains a high priority item because, for the immediate future, improvement in cancer therapy will continue to depend largely on earlier detection and better use of currently available treatment modalities. Both early detection and improved use of therapeutic modalities would be greatly facilitated by the identification of tumor markers that are: (1) specific for the malignant process, (2) tumor-type specific, (3) readily detectable in body fluids and tissue extracts, (4) detectable early in the course of disease before it is clinically evident,

(5) indicative of the overall tumor cell burden in the body, (6) related to the degree of success of anti-cancer therapy, (7) indicative of the presence of micrometastases, and (8) predictive of disease recurrence.

Of the markers that are currently available, human chorionic gonadotropin (hCG) as a marker for choriocarcinoma comes the closest to the ideal.<sup>1</sup> Elevated levels of hCG are indicative of the presence of choriocarcinoma, and a decrease in hCG correlates well with successful therapy. Recurrence of disease is also heralded by increasing hCG levels. Clearly, the ability to follow the therapeutic response of other cancers, in a manner similar to that which can be done for choriocarcinoma with hCG as a biomarker, would be a tremendous boon to cancer therapy.

The reports of Tatarinov<sup>2</sup> and Abelev et al.<sup>3</sup> relating the reappearance of alpha fetoprotein in the serum of adults with hepatocellular carcinoma and teratocarcinoma, and the demonstration by Gold and his colleagues<sup>4,5</sup> of the presence of carcinoembryonic antigen (CEA) in patients with colon cancer have been stimuli to the search for embryonic gene products which are expressed by cancer cells and which may be utilized as indicators of malignant disease. Unfortunately, CEA and other fetal antigens of this type are also associated with certain non-malignant disease states. A number of other oncofetal antigens, hormones, enzymes, and biochemical products of cell metabolism have been found to be associated with human malignant disease. Many of these markers lack specificity in that they may reflect tissue damage resulting from any of a number of mechanisms or may indicate states of hypermetabolism and increased cell turnover which occur in a variety of non-malignant proliferative disorders (Table 1). Nevertheless, in cases where a marker is elevated, even if it is not specific for that tumor type, it may still be very useful in following the course of a given patient's disease and response to therapy. Why the latter is a very important use for biological markers is depicted in Figure 1, which is a schematic plot of the log number of cancer cells in a patient vs. the time after initiation of treatment.<sup>6</sup> In a patient with a tumor burden of  $10^{12}$  cells, a two log kill may be sufficient to put the patient in apparent clinical remission, based on shrinkage of tumor mass, improvement in performance status, etc. Further treatment may reduce the tumor mass to  $10^9$  cells, at which point the tumor usually becomes clinically undetectable. Obviously a patient still harboring a billion cancer cells is not cured. In fact, there is a lot of experimental animal data which indicates that the burden of viable tumor cells has to be reduced to zero in order for cure to be obtained.<sup>7</sup> Thus, one of




Fig. 1. Number of viable cancer cells vs. time after initiation of anticancer therapy. Adapted from Frei.<sup>6</sup>

the important but sometimes overlooked roles for biological markers is to indicate to medical oncologists, radiotherapists, or cancer surgeons whether or not their treatment program has completely eliminated the disease.

It is clear that future research needs to be directed at discovering biological markers which are specific for the malignant process and hopefully also for the tissue of origin of the tumor. In order for a marker to have a significant impact in cancer detection, it should be able to be detected in body fluids when a tumor is smaller than 1 cm in diameter ( $\approx 10^9$  cells). This will require very specific and sensitive assays. It is possible that assays several-fold more sensitive than currently available radioimmunoassays will have to be developed. It is hoped that the subsequent papers presented in this monograph will provide some new insights to basic cancer biologists and clinicians in order to stimulate the search for better cancer markers and to facilitate the utilization of markers that are now being developed, but which have not yet found their way into the clinic.

TABLE 1  
SOME BIOLOGICAL MARKERS OF HUMAN MALIGNANT DISEASE

Classification	Marker	Conditions associated with elevated levels or abnormal isoenzyme patterns	
		Malignant	Nonmalignant
Oncofetal antigens	Alpha <sub>1</sub> -feto-protein	Hepatocellular carcinoma; testicular and ovarian teratocarcinoma; pancreatic, gastric, colonic, and bronchogenic carcinoma	Ataxia telangiectasia, hepatitis, cirrhosis, pregnancy
	CEA	Carcinomas of colon and rectum, pancreas, liver, breast, uterus, ovary, testis, prostate, kidney, bladder and lung; leukemia; lymphoma; neuroblastoma	Cirrhosis, pancreatitis, tuberculosis, chronic bronchitis and emphysema, inflammatory bowel disease, peptic ulcer, colorectal polyps
	Ectopic hormones ACTH	Carcinomas of lung; carcinoid tumors of bronchus, stomach, pancreas; islet cell carcinoma of pancreas; thymoma; medullary carcinoma of thyroid; pheochromocytoma; neuroblastoma and ganglioneuroblastoma; ovarian carcinoma; adenocarcinoma of colon	Nonmalignant neuroendocrine disorders causing Cushing's disease
Enzymes	Calcitonin	Oat cell carcinoma of lung; breast carcinoma; medullary carcinoma of thyroid	Renal insufficiency
	hCG	Choriocarcinoma; testicular embryonal carcinoma; carcinomas of lung, breast, ovary, stomach, small intestine, pancreas, biliary tract, liver, colon/rectum; lymphoma; melanoma	Pregnancy, regional enteritis, ulcerative colitis, hepatic cirrhosis, gastric and duodenal ulcer
	Acid phosphatase	Carcinoma of the prostate; breast carcinoma	Gaucher's disease

Enzymes	Placental alkaline phosphatase	Choriocarcinoma; carcinomas of ovary, pancreas, colon, breast, uterus, bronchus; testicular cancers; reticulum cell sarcoma; Hodgkin's disease; multiple myeloma	Pregnancy
	Non-placental alkaline phosphatase	Osteogenic sarcoma; para-thyroid carcinoma; cancers metastatic to bone, e.g. from prostate, breast; multiple myeloma; infiltrative cancers of liver such as Hodgkin's disease, leukemia, reticulum cell sarcoma	Hepatitis, cirrhosis, amyloidosis, tuberculosis
	Aminopeptidases	Carcinomas of pancreas, liver, stomach, lung; carcinoma metastatic to liver	Viral hepatitis, biliary tract obstruction
	Galactosyl transferase	Carcinomas of lung, breast, esophagus, stomach, pancreas, colon, gallbladder; chronic lymphocytic leukemia	Polycythemia rubra vera, diverticulosis, celiac disease
	Gamma glutamyl transpeptidase	Carcinoma metastatic to liver	Alcoholism, malabsorption syndromes, biliary obstruction, myocardial infarction, neurological diseases, anticonvulsant drug therapy
	5'-Nucleotidase	Carcinoma metastatic to liver (note: activity may be elevated in patients with metastatic carcinoma even though bilirubin is normal)	Hepatobiliary disease
	Ribonuclease	Carcinoma of pancreas	Pancreatitis, obstructive biliary disease, renal insufficiency
	Sialyl transferase	Carcinomas of breast, colon, lung, prostate; leiomyosarcoma; leukemia; lymphoma; melanoma (continued on next page)	Rheumatoid arthritis

TABLE 1 (continued)  
SOME BIOLOGICAL MARKERS OF HUMAN MALIGNANT DISEASE

Classification	Marker	Conditions associated with elevated levels or abnormal isoenzyme patterns	
		Malignant	Nonmalignant
Metabolic products	Beta amino isobutyric acid	Burkitt's lymphoma	
	Hydroxyproline	Carcinoma metastatic to bone	Hydroxyprolinemia, inflammation
	"Minor" nucleosides (e.g. pseudouridine, N <sub>2</sub> , N <sub>2</sub> -dimethylguanosine, 1-methyl inosine)	Leukemia; lymphoma; carcinomas of breast, lung, colon, GI tract; melanoma; brain tumors	Hepatitis, chronic obstructive lung disease, cirrhosis, acute cholecystitis, acute pancreatitis, regional enteritis, rheumatoid arthritis, ulcerative colitis, psoriasis, gout
	Polyamines (putrescine, cadaverine, spermine, spermidine)	Carcinomas of breast, prostate, colon, bladder, testes; leukemia; lymphomas; multiple myeloma; melanoma; fibrosarcoma; liposarcoma	Pernicious anemia, hemolytic anemia, rheumatoid arthritis, polymyositis, chronic obstructive lung disease, tuberculosis, psoriasis, liver abscess
	Protein bound fucose	Carcinomas of breast, lung, stomach, colon, thyroid, liver, pancreas, salivary gland, cervix, ovary	Acute ileitis, ulcerative colitis, hyperthyroidism, tuberculosis, emphysema, uremia
	Complement component C <sub>3</sub> derived polypeptide (C3DP)	Carcinomas of breast, ovary, cervix, prostate, lung, larynx, stomach, pancreas, rectum, liver; brain tumors; leukemia; lymphoma; melanoma	Chronic leukopenia, hemochromatosis, mastitis, peritonitis
Serum protein degradation products	Fibrin degradation products	Carcinoma of ovary, prostate	Endometriosis, uterine myoma, myometriosiis, genitourinary tract infection, renal disease



## REFERENCES

1. Bagshawe, K.D. (1973) *Adv. Cancer Res.*, 18, 231-263.
2. Tatarinov, V.S. (1964) *Vop. Med. Khim.*, 10, 90-91.
3. Abelev, G.I., Assecritova, I.V., Kraevsky, N.A., Perova, S.D. and Perevodchikova, N.I. (1967) *Int. J. Cancer*, 2, 551-558.
4. Gold, P. and Freedman, S.O. (1965) *J. Exp. Med.*, 121, 439-462.
5. Thomson, D.M.P., Krupey, J., Freedman, S.O. and Gold, P. (1969) *Proc. Natl. Acad. Sci. USA*, 64, 161-167.
6. Frei, E., III (1972) *Cancer Res.*, 32, 2593-2607.
7. Skipper, H.E., Schabel, F.M., Jr. and Wilcox, W.S. (1964) *Cancer Chemother. Rep.*, 35, 1-111.